Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2005 Dec 7;25(4):475–482. doi: 10.1002/jmv.1890250411

Evaluation of an enzyme‐linked immunosorbent assay that measures rhinovirus‐specific antibodies in human sera and nasal secretions

Wendy S Barclay 1, Kathleen A Callow 1, Marianne Sergeant 1, Widad Ai‐Nakib 1,
PMCID: PMC7166658  PMID: 2844987

Abstract

Rhinovirus‐specific antibodies have traditionally been detected by their ability to neutralise the homologous rhinovirus serotype in tissue culture. Recently, however, we have described an enzyme‐linked immunosorbent assay that detects rhinovirus‐specific antibodies in sera and nasal secretions [Barclay and Al‐Nakib, 1987]. Here we describe an evaluation of the ELISA in a study involving 71 adult volunteers inoculated intranasally with human rhinovirus type 2 (HRV‐2). Pre‐and post‐inoculation serum samples and pre‐inoculation nasal washings were tested for the presence of HRV‐2‐specific antibodies by ELISA. Such antibodies were associated with protection against infection when present locally in nasal secretions, but when also present in the serum they were associated with protection against both infection and the development of illness. The antibody concentrations showed strong correlation with each other and with that of antibodies detected by the neutralisation test. Following HRV‐2 infection, rises in HRV‐2‐specific IgA in sera detected by ELISA occurred more frequently than rises in neutralizing antibody. These results suggest that the ELISA is a sensitive and reliable indicator of recent infection, as well as a predictor of homologous immune status.

Keywords: immunoglobulin, human rhinovirus type 2, common cold, IgA, IgG

References

  1. Al‐Nakib W, Higgins PG, Barrow GI, Balstone G, Tyrrell DAJ (1987): Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. Journal of Antimicrobial Chemotherapy 20: 893–901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barclay WS, Al‐Nakib W (1987): An ELISA for the detection of rhinovirus specific antibody in serum and nasal secretion. Journal of Virological Methods 15: 53–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beare AS, Reed SE (1977): The study of antiviral compounds in volunteers In Oxford JS. (ed): “Chemoprophylaxis and Virus Infections of the Respiratory Tract,” Vol. 11 Cleveland: CRC Press, pp 27–55. [Google Scholar]
  4. Callow KA (1985): Effect of specific humoral immunity and some non‐specific factors on resistance of volunteers to respiratory coronavirus infection. Journal of Hygiene (Cambridge) 95: 173–189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Couch RB (1984): The common cold: Control? The Journal of Infectious Diseases 150: 167–173. [DOI] [PubMed] [Google Scholar]
  6. Doggett JE (1965): Prevention of colds by vaccination against a rhinovirus: A report by the scientific committee on common cold vaccines. British Medical Journal 1: 134–1349. [PMC free article] [PubMed] [Google Scholar]
  7. Hamparian VV (1979): Rhinoviruses In Lennette EH, Schmidt NJ. (eds): “Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections.” Washington, DC: American Public Health Association, pp. 535–577. [Google Scholar]
  8. Lonberg‐Holm K, Yin FH (1973): Antigenic determinants of infective and inactivated human rhinovirus type 2. Journal of Virology 112: 114–123. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Medical Virology are provided here courtesy of Wiley

RESOURCES